the production of two cellular entrance techniques, including nanoparticles, whereas VascVersa is a new regenerative startup based in Belfast and concentrates on chronic wound treatments. Other partners of the facility are Chiesi Limited, Cytiva, NHS Blood and Transport, and the University of Edinburgh.
This recent announcement is the result of the collaboration between NA-ATTC and iMatch – Innovate Manchester Advanced Therapy Centre Hub in order to expand operations and increase patient access to ATMPs. Aptus Clinical, AstraZeneca, and Formedix are among iMatch’s business partners. Additionally, the ATTC operates a treatment center in the Midlands and Wales, known as MW-ATTC.
